BR112018000179A2 - composto, composição, e, método para tratar a infecção pelo hiv. - Google Patents

composto, composição, e, método para tratar a infecção pelo hiv.

Info

Publication number
BR112018000179A2
BR112018000179A2 BR112018000179A BR112018000179A BR112018000179A2 BR 112018000179 A2 BR112018000179 A2 BR 112018000179A2 BR 112018000179 A BR112018000179 A BR 112018000179A BR 112018000179 A BR112018000179 A BR 112018000179A BR 112018000179 A2 BR112018000179 A2 BR 112018000179A2
Authority
BR
Brazil
Prior art keywords
compound
composition
hiv infection
treating hiv
compounds
Prior art date
Application number
BR112018000179A
Other languages
English (en)
Inventor
Narasimhulu Naidu B
F Kadow John
Patel Manoj
Sivaprakasam Prasanna
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of BR112018000179A2 publication Critical patent/BR112018000179A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

são descritos compostos de fórmula i, incluindo sais farmaceuticamente aceitáveis, composições farmacêuticas que compreendem os compostos, métodos para produzir os compostos e a sua utilização na inibição do hiv integrase e tratamento dos infectados com hiv ou aids.
BR112018000179A 2015-07-08 2016-07-06 composto, composição, e, método para tratar a infecção pelo hiv. BR112018000179A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189975P 2015-07-08 2015-07-08
PCT/IB2016/054048 WO2017006260A1 (en) 2015-07-08 2016-07-06 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
BR112018000179A2 true BR112018000179A2 (pt) 2018-09-04

Family

ID=56373096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000179A BR112018000179A2 (pt) 2015-07-08 2016-07-06 composto, composição, e, método para tratar a infecção pelo hiv.

Country Status (11)

Country Link
US (1) US10221156B2 (pt)
EP (1) EP3319957A1 (pt)
JP (1) JP2018519348A (pt)
KR (1) KR20180025926A (pt)
CN (1) CN107835808A (pt)
AU (1) AU2016290151A1 (pt)
BR (1) BR112018000179A2 (pt)
CA (1) CA2991268A1 (pt)
IL (1) IL256449A (pt)
RU (1) RU2018102554A (pt)
WO (1) WO2017006260A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019244066A2 (en) * 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
ES2402322T3 (es) 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP2220076B1 (en) 2007-11-15 2012-01-18 Boehringer Ingelheim International GmbH Inhibitors of human immunodeficiency virus replication
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8609653B2 (en) * 2011-07-15 2013-12-17 Glaxosmithkline Llc Azaindole compounds and methods for treating HIV
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105189511B (zh) 2013-03-13 2017-05-24 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
EP2970273B1 (en) * 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
US9193720B2 (en) * 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
EP3319957A1 (en) 2018-05-16
RU2018102554A (ru) 2019-08-08
KR20180025926A (ko) 2018-03-09
IL256449A (en) 2018-02-28
US10221156B2 (en) 2019-03-05
US20180162831A1 (en) 2018-06-14
JP2018519348A (ja) 2018-07-19
WO2017006260A1 (en) 2017-01-12
CN107835808A (zh) 2018-03-23
CA2991268A1 (en) 2017-01-12
AU2016290151A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201792116A1 (ru) Ингибитор янус-киназы
BR112015021027A2 (pt) compostos terapêuticos
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
BR112016006651B8 (pt) compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
BR112018005904A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
BR112018005870A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
BR112017017500A2 (pt) derivado de quinolina para uso no tratamento e prevenção de infecções virais
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
EA201890532A1 (ru) Новые аннелированные бензамиды

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]